Septerna Inc/$SEPN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Septerna Inc
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
- Ticker
- $SEPN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 123
- Headquarters
- South San Francisco, United States
- Website
- www.septerna.com
Septerna Inc Metrics
BasicAdvanced
$2.1B
-
-$0.54
-
-
Price and volume
Market cap
$2.1B
52-week high
$51.10
52-week low
$17.55
Average daily volume
374K
Financial strength
Current ratio
4.995
Quick ratio
4.895
Long term debt to equity
0.052
Total debt to equity
0.058
Profitability
EBITDA (TTM)
-54.395
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-24.51%
Operating margin (TTM)
-56.68%
Effective tax rate (TTM)
-5.77%
Revenue per employee (TTM)
$800,000
Management effectiveness
Return on assets (TTM)
-7.13%
Return on equity (TTM)
-6.34%
Valuation
Price to revenue (TTM)
19.882
Price to book
5.19
Price to tangible book (TTM)
5.19
Price to free cash flow (TTM)
18.706
Free cash flow yield (TTM)
5.35%
Free cash flow per share (TTM)
2.352
Growth
Revenue change (TTM)
13,520.11%
Earnings per share change (TTM)
-80.92%
Bulls say / Bears say
SEP-631 produced a dose-dependent reduction in an induced skin response in Phase 1, with tolerability and drug levels supporting once-daily dosing. This is early human proof that the MRGPRX2 mechanism can be engaged. (SEC)
SEP-479 has shown a three-to-four-day half-life in people, which the company expects could support once-daily oral dosing for hypoparathyroidism. Its full Phase 1 results are due in Q1 2027. (SEC)
Septerna ended June with $516.5 million in cash and expects to fund planned operations into at least 2029. Novo Nordisk also reimburses research costs under their collaboration, helping Septerna advance partnered programmes without bearing their full development expense. (SEC)
SEP-479’s half-life is encouraging, but its Phase 1 safety and pharmacodynamic results are not yet available; the full readout was pushed to Q1 2027 as the multiple-dose study was extended. That leaves a key test of the lead asset outstanding for longer. (SEC)
Septerna has shifted away from a large Phase 2b trial of SEP-631 in chronic spontaneous urticaria towards smaller signal-finding studies. Management noted that two trials in the indication had already failed, raising the risk that this disease setting may not show a useful treatment effect. (Investing.com)
The company remains loss-making and has no product sales: Q2 revenue came from its Novo collaboration, while operating expenses exceeded revenue. The partnership supports development, but Septerna still needs clinical success and eventual approval before it can build a product-based business. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2026.
Septerna Inc Financial Performance
Revenues and expenses
Septerna Inc Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Septerna Inc
Fund name | Fund size | $SEPN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.13% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.13% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.